Page 7 - CUA KIDNEY CANCER HANDBOOK 2020
P. 7
Introduction
In October 2019, the Kidney Cancer Research Network of Canada (KCRNC) published
an updated consensus report on the management of advanced kidney cancer (Hotte
SJ, et al. Can Urol Assoc J. 2019;13(10):343-54.) Advanced kidney cancer has
seen an expansion in the treatment armamentarium from largely targeted systemic
therapies to now include immunotherapy options. This shift in therapeutic strategy
has implications for patient care in routine clinical practice, in terms of patient
baseline assessment, evaluating disease response, as well as toxicity monitoring
and management.
This handbook, Practical Approaches to Managing Advanced Kidney Cancer, aligns
with the published consensus statements. Please note that unanimous consensus
was not reached for all treatment options; the published recommendations reflect
the majority position. With this in mind, this booklet aims to provide a concise
overview of the practical aspects of patient management throughout the treatment
continuum. The information presented in this handbook is not definitive guidance but
rather is meant to support discussions with the patient and multidisciplinary team
regarding both short- and long-term treatment planning and patient management.
The Health Canada approval status of agents mentioned in this handbook reflects
the products’ indicated uses at the time of publishing. Please consult individual
Product Monographs (through the Health Canada Drug Product Database) for the
most current indicated uses. The Canadian Urological Association aims to update
the content as the treatment landscape changes and new agents become available.
We welcome your feedback to ensure this handbook serves as a helpful resource
in your practice.
Practical Approaches to Managing Advanced Kidney Cancer 5